Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer

Condition:   Head Neck Cancer Squamous Cell Recurrent
Interventions:   Drug: Cetuximab;   Drug: Methotrexate
Sponsors:   Gustave Roussy, Cancer Campus, Grand Paris;   National Cancer Institute, France;   Ligue contre le cancer, France;   Merck Serono International SA
Recruiting - verified February 2016

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1ol0MYZ
via IFTTT